LeMaitre Vascular Inc. (LMAT)

LeMaitre Vascular remains a long-term compounder, delivering strong Q2 results with 15% sales growth, robust margins, and increased dividends. LMAT's investment thesis is supported by pricing power, a...

LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.

I like that Telus is deleveraging, and I'll be following how much revenue the co-location of cell towers could bring to the table now that Telus's tower network is half-owned by a third party. I see l...

LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

LeMaitre (LMAT) Q2 Revenue Jumps 15%

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants David B. Roberts - President & Director Dorian LeBlanc - Chief Financial Officer ...

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.52 per share a year ago.

Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the...

We avoid very high-yielding stocks, as the best way to grow richer over time is to own a diversified basket of dividend growth stocks. Today, we're highlighting a leading alternative asset manager, a ...